Pharming receives FDA approval for Joenjaas to treat rare immunodeficiency

By NS Healthcare Staff Writer

27 Mar 23

Joenja is indicated for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), which is caused by gain of function…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Gilead Sciences licenses Nurix’ protein degrader molecule NX‑0479

By NS Healthcare Staff Writer

21 Mar 23

Designated as GS-6791, NX‑0479 is a bivalent degrader which is the first development candidate resulting from the previously…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Mediar secures $85m in Series A funding to advance fibrosis therapies portfolio

By NS Healthcare Staff Writer

16 Mar 23

The company will use the funding to advance its portfolio which comprises three novel antibody treatments that are…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Sanofi agrees to acquire Provention Bio for $2.9bn

By NS Healthcare Staff Writer

14 Mar 23

The deal will add Provention Bio’s Tzield disease-modifying treatment for delay of Stage 3 type 1 diabetes to…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

AstraZeneca’s Tagrisso meets key secondary endpoint of OS in ADAURA trial

By NS Healthcare Staff Writer

10 Mar 23

The late-stage trial compared the lung cancer drug with placebo in the late-stage trial in 682 patients having…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

CSL secures EC approval for Hemgenix to treat severe haemophilia B

By NS Healthcare Staff Writer

21 Feb 23

Hemgenix is an adeno-associated virus (AAV)-based gene therapy indicated for the treatment of severe and moderately severe haemophilia…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Bavarian Nordic to buy Emergent’s travel health business for up to $380m

By NS Healthcare Staff Writer

16 Feb 23

Bavarian Nordic will obtain rights to Emergent’s vaccine candidates, Vivotif to prevent typhoid fever, Vaxchora to prevent cholera,…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Orphagen secures FDA rare paediatric disease status for OR-449 to treat ACC

By NS Healthcare Staff Writer

18 Jan 23

The firm is developing the OR-449 for both the adult and paediatric forms of ACC as well as…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

BioNTech to acquire AI drug discovery start-up InstaDeep for £362m

By NS Healthcare Staff Writer

11 Jan 23

The acquisition builds on a multi-year strategic collaboration between BioNTech and InstaDeep and is expected to add around…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

AbbVie, Anima Biotech collaborate to develop mRNA biology modulators

By NS Healthcare Staff Writer

11 Jan 23

Anima Biotech will get a $42m upfront payment with the possibility of further payments towards research and development…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates